Alphabet Inc Class A vs Heron Therapeutics Inc — how do they compare? Alphabet Inc Class A trades at $351.66 (market cap $4.24T), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: Alphabet Inc Class A is far larger — about 62343.8× Heron Therapeutics Inc's market cap, and Alphabet Inc Class A pays a 0.25% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 85 Days and Heron Therapeutics Inc for 35 Days on average.
| GOOGL | HRTX | |
|---|---|---|
Market Cap | $4.24T | $68.01M |
Volume | 23,392,850 | 1,891,941 |
Sector | Media | Health |
52-Week High | $402.62 | $1.49 |
52-Week Low | $236.59 | $0.27 |
Typical Hold Time | 85 Days | 35 Days |
Enterprise Value | $4.13T | $174.75M |
Dividend Yield | 0.25% | — |
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $348.29, down 0.63% on the day, amid strong fundamental performance with Q2 2026 EPS beating expectations by 217%. The stock shows bullish technical signals with moving averages supporting upward momentum, while maintaining robust profitability metrics including 54.77% net income margin and 49.55% ROE. Recent developments include YouTube subscription price increases and AI infrastructure partnerships driving growth prospects.
With 87% analyst buy ratings and a $431.83 consensus target representing 24% upside, GOOGL presents compelling value at current levels. Key risks include antitrust scrutiny and AI competition, but strong cash flow generation and consistent earnings beats support long-term growth trajectory. The company's diversified revenue streams and AI leadership position it well for sustained outperformance.
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →